The first twice-daily injectable HIV prevention drug based on lenacapavir has received CHMP recommendation for authorization, promising an effective and affordable solution.
Cristina Petrache
Health
Foto pexels.com
Always see our news on Google
Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Latest News
17:39
Putin wants to transfer some Russian factories to Africa, amid Western sanctions affecting Russia's economy
17:30
Finnish police have opened a criminal investigation into alleged environmental damage at the construction site of a Google data center
17:30
Some Romanians believed that Călin Georgescu’s son had won the Ballon d’Or. A satirical post sparked a wave of congratulations on TikTok
17:21
The European Commission wants to postpone the bans on social media for minors by at least one year
17:09
Hungary will maintain the nuclear agreement with the US, signed during the Orban government
See more news
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
